Literature DB >> 118548

The dosing schedule dependent toxicities of adriamycin in beagle dogs and rhesus monkeys.

E J Gralla, R W Fleischman, Y K Luthra, S W Stadnicki.   

Abstract

The toxic effects of Adriamycin were studied following i.v. administration of from 10.0 mg/kg to 0.039 mg/kg (200--0.780 mg/m2) to beagle dogs, and from 5.83 mg/kg to 0.625 mg/kg (49.9--7.5 mg/m2) in rhesus monkeys by a variety of short and long term treatment schedules. 5 daily doses and 1 dose every 3 weeks were given for both species and, only in dogs, as single injections, 10 daily treatments and 5 daily doses followed by 9 days rest, repeated 3 times. In both species, short term administration of toxic doses caused weight losses, anorexia, diarrhea, atypical oesophageal and intestinal mucosa, bone marrow hypoplasia, lymphoid atrophy and alopecia. Specific adverse responses seen only in monkeys were hypocalcemia, hypomagnesemia, atypical buccal mucosa and reddish urinary pigmentation. Testicular degeneration and prostatic atrophy were produced in dogs. The triweekly treatment schedule caused an additional toxicity at lower doses. In both species a cardiotoxicity syndrome developed with pulmonary oedema and centrolobular hepatic necrosis, plus focal necrosis and vacuolization in cardiac myocytes. Clinical signs of cardiac dysfunction were EKG arrhythmias in dogs, and peripheral oedema, ascites and hydrothorax in monkeys.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 118548

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  4 in total

1.  Accidental overdose of mitoxantrone in three patients.

Authors:  W Siegert; W Hiddemann; R Koppensteiner; T Büchner; M Essink; D Huhn; M Jung; L Marosi; T Martin; E Minar
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

2.  Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.

Authors:  T Noda; T Watanabe; A Kohda; S Hosokawa; T Suzuki
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

Review 3.  Doxorubicin (adriamycin) cardiomyopathy.

Authors:  E Saltiel; W McGuire
Journal:  West J Med       Date:  1983-09

4.  Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD).

Authors:  Robert T O'Donnell; Shiloh M Martin; Yunpeng Ma; William C Zamboni; Joseph M Tuscano
Journal:  Invest New Drugs       Date:  2009-03-24       Impact factor: 3.850

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.